The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review (Q37954675)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 December 2011

Language	Label	Description	Also known as
English	The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review	scientific article published on 27 December 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

type 2 diabetes

0 references

hospitalization

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

author name string

J H Best

1

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

K Lavillotti

2

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

M B DeYoung

3

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

L P Garrison

4

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

publication date

27 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

387-398

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Exenatide therapy in insulin-treated type 2 diabetes and obesity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Durability of Effects of Exenatide Treatment on Glycemic Control, Body Weight, Systolic Blood Pressure, C-Reactive Protein, and Triglyceride Concentrations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Standards of Medical Care in Diabetes—2011

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01533.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01533.X

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37954675&oldid=2122494786"